Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data

  • Celldex Therapeutics Inc's (NASDAQ:CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab.
  • Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild neutrophil decreases, noting a single Grade 3 case.
    • One patient had values that never got below 1,500 and was considered Grade 1 with the scale used. 
    • Two patients had levels dip below 1,500 at isolated time points and recovered above this level.
    • One patient dipped below 1,000 at two isolated time points and was above this subsequently. 
  • There was no pattern of further neutrophil decreases in these patients, and they returned to normal by the end of the study. 
  • Cantor says that while some investors viewed this as a concern, others did not, in light of the details behind these four individuals.
  • According to some investors, the safety data addressed an overhang showing that chronic dosing does not further enhance KIT suppression but prolongs the effects.
  • "On efficacy, we have not received much pushback on these data. The sentiment suggests that the company achieved at least the minimum bar of investor expectations," Cantor writes.
  • Cantor has an Overweight rating on the shares with a price target of $59.00.
  • Price Action: CLDX shares are up 8.63% at $24.66 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.